KFF November 26, 2024
Juliette Cubanski, Elizabeth Williams

The Biden administration has proposed to allow Medicare and require Medicaid to cover drugs used to treat obesity by reinterpreting the statutory language that currently prohibits coverage of drugs used for weight loss under Medicare and permits but does not require states to cover these drugs for weight loss under Medicaid. This reinterpretation reflects an evolution in the understanding of obesity as a disease and weight loss as conferring real health benefits in people with obesity rather than being merely for cosmetic purposes. It also comes amidst high and growing demand for and use of a relatively new class of highly effective, but also very expensive, drugs being used to treat obesity, known as GLP-1s.

Under current law, people on...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicaid, Medicare, Patient / Consumer, Pharma / Biotech, Provider
On Heels of FDA Nod, BridgeBio’s Rival to Blockbuster Pfizer Drug Wins European Approval
The First Diagnostic Immunome
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Medicare’s Drug Price Negotiation And Innovation: What’s Off The Table Matters Too
Stakeholder Management and Interoperability of Biosimilars

Share This Article